A mid-sized pharmaceutical client was in the process of developing a pediatric indication product for a rare disease. Patient data indicated that the targeted therapeutic would see high utilization within both Medicaid and the supplemental Children’s Health program. Catalyst was engaged to develop a public payor strategy to secure coverage through state Medicaid pharmacy and therapeutics (P&T) committees while managing the statutory and supplemental rebate requirements states were likely to impose.
A small start-up device manufacturer received breakthrough designation from the FDA. Having never launched a product in the US before, the company asked Catalyst to develop a coverage and payor strategy designed to drive uptake and utilization.
Sign up for periodic updates on regulatory policy and events we are attending
